John Reynolds

Prof. John Reynolds

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Brain Stimulation
Verified
Journal Article
Closed access
LBL.J. Boddington
L.J. Boddington
JRJohn Reynolds
John Reynolds

23 August 2022 in Biology
Verified
Journal Article
Open access
PDF file
ABAshik Banstola
Ashik Banstola
JRJohn Reynolds
John Reynolds
An essential aim of biomedical research is to translate basic science information obtained from preclinical research using small and large animal models into clinical practice for the benefit of humans. Research on rodent models has enhanced our understanding of complex pathophysiology, thus providing potential translational pathways. However, the success of translating drugs from pre-clinical to clinical therapy has been poor, partly due to the choice of experimental model. The sheep model, in particular, is being increasingly applied to the field of biomedical research and is arguably one of the most influential models of human organ systems. It has provided essential tools and insights into cardiovascular disorder, orthopaedic examination, reproduction, gene therapy, and new insights into neurodegenerative research. Unlike the widely adopted rodent model, the use of the sheep model has an advantage over improving neuroscientific translation, in particular due to its large body size, gyrencephalic brain, long lifespan, more extended gestation period, and similarities in neuroanatomical structures to humans. This review aims to summarise the current status of sheep to model various human diseases and enable researchers to make informed decisions when considering sheep as a human biomedical model.

24 August 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SFSimon D. Fisher
Simon D. Fisher
PRPaul B. Robertson
Paul B. Robertson
MBMelony J. Black
Melony J. Black
PRPeter Redgrave
Peter Redgrave
MSMark A. Sagar
Mark A. Sagar
JRJohn Reynolds
John Reynolds
Plasticity at synapses between the cortex and striatum is considered critical for learning novel actions. However, investigations of spike-timing-dependent plasticity (STDP) at these synapses have been performed largely in brain slice preparations, without consideration of physiological reinforcement signals. This has led to conflicting findings, and hampered the ability to relate neural plasticity to behavior. Using intracellular striatal recordings in intact rats, we show here that pairing presynaptic and postsynaptic activity induces robust Hebbian bidirectional plasticity, dependent on dopamine and adenosine signaling. Such plasticity, however, requires the arrival of a reward-conditioned sensory reinforcement signal within 2 s of the STDP pairing, thus revealing a timing-dependent eligibility trace on which reinforcement operates. These observations are validated with both computational modeling and behavioral testing. Our results indicate that Hebbian corticostriatal plasticity can be induced by classical reinforcement learning mechanisms, and might be central to the acquisition of novel actions.

11 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JRJohn Reynolds
John Reynolds
RARiccardo Avvisati
Riccardo Avvisati
PDPaul D. Dodson
Paul D. Dodson
SFSimon D. Fisher
Simon D. Fisher
MOManfred J. Oswald
Manfred J. Oswald
YZYan-Feng Zhang
Yan-Feng Zhang
Dopamine-dependent long-term plasticity is believed to be a cellular mechanism underlying reinforcement learning. In response to reward and reward-predicting cues, phasic dopamine activity potentiates the efficacy of corticostriatal synapses on spiny projection neurons (SPNs). Since phasic dopamine activity also encodes other behavioural variables, it is unclear how postsynaptic neurons identify which dopamine event is to induce long-term plasticity. Additionally, it is unknown how phasic dopamine released from arborised axons can potentiate targeted striatal synapses through volume transmission. To examine these questions we manipulated striatal cholinergic interneurons (ChIs) and dopamine neurons independently in two distinct in vivo paradigms. We report that long-term potentiation (LTP) at corticostriatal synapses with SPNs is dependent on the coincidence of pauses in ChIs and phasic dopamine activation, critically accompanied by SPN depolarisation. Thus, the ChI pause defines the time window for phasic dopamine to induce plasticity, while depolarisation of SPNs constrains the synapses eligible for plasticity.

11 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KGKushan Gandhi
Kushan Gandhi
ABAnita Barzegar-Fallah
Anita Barzegar-Fallah
ABAshik Banstola
Ashik Banstola
SRShakila B Rizwan
Shakila B Rizwan
JRJohn Reynolds
John Reynolds
Ultrasound-mediated blood–brain barrier (BBB) disruption has garnered focus as a method of delivering normally impenetrable drugs into the brain. Numerous studies have investigated this approach, and a diverse set of ultrasound parameters appear to influence the efficacy and safety of this approach. An understanding of these findings is essential for safe and reproducible BBB disruption, as well as in identifying the limitations and gaps for further advancement of this drug delivery approach. We aimed to collate and summarise protocols and parameters for achieving ultrasound-mediated BBB disruption in animal and clinical studies, as well as the efficacy and safety methods and outcomes associated with each. A systematic search of electronic databases helped in identifying relevant, included studies. Reference lists of included studies were further screened to identify supplemental studies for inclusion. In total, 107 articles were included in this review, and the following parameters were identified as influencing efficacy and safety outcomes: microbubbles, transducer frequency, peak-negative pressure, pulse characteristics, and the dosing of ultrasound applications. Current protocols and parameters achieving ultrasound-mediated BBB disruption, as well as their associated efficacy and safety outcomes, are identified and summarised. Greater standardisation of protocols and parameters in future preclinical and clinical studies is required to inform robust clinical translation.

1 November 2014 in Experimental Neurology
Verified
Journal Article
Closed access
MBMelissa D. Barry
Melissa D. Barry
LBLaura J. Boddington
Laura J. Boddington
KIKajsa M. Igelström
Kajsa M. Igelström
JGJason P. Gray
Jason P. Gray
JSJonathan Shemmell
Jonathan Shemmell
JRJohn Reynolds
John Reynolds